Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
- PMID: 23900966
- DOI: 10.1002/biof.1125
Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
Abstract
Cancer immunosurvelliance usually leads to formation of cancer cells that have been "immunoedited" to resist anti-tumor immunity. One of the consequences of immunoediting that is, reduced immunogenicity, is an important roadblock in revival of stable and long-lasting anti-tumor immune responses. Research done during the last decade has shown that emission by the dying cancer cells of immunomodulatory factors or damage-associated molecular patterns (DAMPs), which can act as danger signals, is a critical event in accentuating the immunogenicity of cancer cells, in response to a subset of anticancer treatments. Recent evidence has defined that an apoptotic cell death subroutine and its underlying biochemistry, which has been termed as "immunogenic cell death (ICD)" or "immunogenic apoptosis," is required for the efficient emission of DAMPs and inciting anti-tumor immunity. Here, we review the basic concepts of ICD, like cancer immunogenicity, danger signals, and DAMPs. Moreover, we discuss the emerging molecular links between endoplasmic reticulum (ER) stress, induction of a viral response-like gene expression, danger signals, and anti-tumor immunity. We envisage that along with ER stress-based trafficking of DAMPs (which is a "short-range communicator" of danger), the accompanying induction of a viral response-like gene expression and the secretion of anti-tumorigenic cytokines may become a crucial signature of ICD induction by anticancer therapy.
Keywords: ICD inducers; anti-tumor immunity; immunogenic cell death; tumor immunology; viral response.
Copyright © 2013 International Union of Biochemistry and Molecular Biology, Inc.
Similar articles
-
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.Immunol Rev. 2017 Nov;280(1):126-148. doi: 10.1111/imr.12574. Immunol Rev. 2017. PMID: 29027218 Review.
-
Immunogenic cell death.Int J Dev Biol. 2015;59(1-3):131-40. doi: 10.1387/ijdb.150061pa. Int J Dev Biol. 2015. PMID: 26374534 Review.
-
The PERKs of damage-associated molecular patterns mediating cancer immunogenicity: From sensor to the plasma membrane and beyond.Semin Cancer Biol. 2015 Aug;33:74-85. doi: 10.1016/j.semcancer.2015.03.010. Epub 2015 Apr 13. Semin Cancer Biol. 2015. PMID: 25882379 Review.
-
Immunogenic Apoptotic Cell Death and Anticancer Immunity.Adv Exp Med Biol. 2016;930:133-49. doi: 10.1007/978-3-319-39406-0_6. Adv Exp Med Biol. 2016. PMID: 27558820 Review.
-
Danger signalling during cancer cell death: origins, plasticity and regulation.Cell Death Differ. 2014 Jan;21(1):26-38. doi: 10.1038/cdd.2013.48. Epub 2013 May 17. Cell Death Differ. 2014. PMID: 23686135 Free PMC article. Review.
Cited by
-
Mechanisms and immunogenicity of nsPEF-induced cell death in B16F10 melanoma tumors.Sci Rep. 2019 Jan 23;9(1):431. doi: 10.1038/s41598-018-36527-5. Sci Rep. 2019. PMID: 30674926 Free PMC article.
-
Using PAMPs and DAMPs as adjuvants in cancer vaccines.Hum Vaccin Immunother. 2021 Dec 2;17(12):5546-5557. doi: 10.1080/21645515.2021.1964316. Epub 2021 Sep 14. Hum Vaccin Immunother. 2021. PMID: 34520322 Free PMC article. Review.
-
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015. Front Immunol. 2015. PMID: 26635802 Free PMC article.
-
Trial watch: Dendritic cell-based anticancer immunotherapy.Oncoimmunology. 2017 May 12;6(7):e1328341. doi: 10.1080/2162402X.2017.1328341. eCollection 2017. Oncoimmunology. 2017. PMID: 28811970 Free PMC article. Review.
-
Damage-Associated Molecular Patterns As Double-Edged Swords in Sepsis.Antioxid Redox Signal. 2021 Nov 20;35(15):1308-1323. doi: 10.1089/ars.2021.0008. Epub 2021 Mar 30. Antioxid Redox Signal. 2021. PMID: 33587003 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources